Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on invested capital (ROIC) is N/A as of the fiscal period ended Tuesday, March 31, 2026.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q1 FY2026 (2026-03-31): -181.70%.
RETURN ON INVESTED CAPITAL (ROIC)
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-282.12%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-131.29%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-82.22%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
-73.42%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Karyopharm Therapeutics Inc.
Market Cap
$15.10M
Return on Invested Capital (ROIC)
N/A
TTM Avg
-282.12%
3Y Avg
-131.29%
5Y Avg
-82.22%
Market Cap
$14.95M
Return on Invested Capital (ROIC)
-48.04%
TTM Avg
-66.55%
3Y Avg
-57.55%
5Y Avg
-44.03%
Market Cap
$15.42M
Return on Invested Capital (ROIC)
-497.29%
TTM Avg
-141.17%
3Y Avg
-111.65%
5Y Avg
-80.50%
Market Cap
$14.51M
Return on Invested Capital (ROIC)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$14.44M
Return on Invested Capital (ROIC)
-13.15%
TTM Avg
-23.00%
3Y Avg
-25.06%
5Y Avg
-54.51%
Market Cap
$15.75M
Return on Invested Capital (ROIC)
-41.81%
TTM Avg
-159.62%
3Y Avg
-298.97%
5Y Avg
-203.41%
Market Cap
$16.07M
Return on Invested Capital (ROIC)
-273.70%
TTM Avg
-707.06%
3Y Avg
-535.27%
5Y Avg
-358.40%
Market Cap
$13.72M
Return on Invested Capital (ROIC)
-57.53%
TTM Avg
-660.45%
3Y Avg
-553.22%
5Y Avg
-396.73%
Market Cap
$13.89M
Return on Invested Capital (ROIC)
-91.74%
TTM Avg
-119.31%
3Y Avg
-112.64%
5Y Avg
-88.90%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Karyopharm Therapeutics Inc. (KPTI) | $15.10M | N/A | -282.12% | -131.29% | -82.22% |
| Pasithea Therapeutics Corp. (KTTA)vs › | $14.95M | -48.04% | -66.55% | -57.55% | -44.03% |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.42M | -497.29% | -141.17% | -111.65% | -80.50% |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.51M | N/A | N/A | N/A | N/A |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.44M | -13.15% | -23.00% | -25.06% | -54.51% |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.75M | -41.81% | -159.62% | -298.97% | -203.41% |
| BioCardia, Inc. (BCDA)vs › | $16.07M | -273.70% | -707.06% | -535.27% | -358.40% |
| Vyome Holdings, Inc. (HIND)vs › | $13.72M | -57.53% | -660.45% | -553.22% | -396.73% |
| IN8bio, Inc. (INAB)vs › | $13.89M | -91.74% | -119.31% | -112.64% | -88.90% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.89M | -67.62% | -48.11% | -41.05% | -37.60% |
ROIC
N/A
ROE
N/A
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-03-31 | -181.70% |
| 2025-12-31 | -242.75% |
| 2025-09-30 | -477.18% |
| 2025-06-30 | -316.53% |
| 2025-03-31 | -192.46% |
| 2024-12-31 | -123.67% |
| 2024-09-30 | -98.43% |
| 2024-06-30 | -83.75% |
| 2024-03-31 | -95.17% |
| 2023-12-31 | -75.77% |
| 2023-09-30 | -60.42% |
| 2023-06-30 | -52.40% |
| 2023-03-31 | -52.42% |
| 2022-12-31 | -48.66% |
| 2022-09-30 | -36.21% |
| 2022-06-30 | -38.33% |
| 2022-03-31 | -35.35% |
| 2021-12-31 | -42.43% |
| 2021-09-30 | -98.42% |
| 2021-06-30 | -81.24% |
| 2021-03-31 | -83.07% |
| 2020-12-31 | -67.97% |
| 2020-09-30 | -62.48% |
| 2020-06-30 | -51.71% |
| 2020-03-31 | -46.86% |
| 2019-12-31 | -76.13% |
| 2019-09-30 | -78.70% |
| 2019-06-30 | -103.54% |
| 2019-03-31 | -84.59% |
| 2018-12-31 | -61.12% |
| 2018-09-30 | -90.73% |
| 2018-06-30 | -65.34% |
| 2018-03-31 | -139.71% |
| 2017-12-31 | -99.78% |
| 2017-09-30 | -82.91% |
| 2017-06-30 | -67.13% |
| 2017-03-31 | -81.21% |
| 2016-12-31 | -67.56% |
| 2016-09-30 | -66.92% |
| 2016-06-30 | -75.78% |
| 2016-03-31 | -67.23% |
| 2015-12-31 | -59.45% |
| 2015-09-30 | -52.00% |
| 2015-06-30 | -42.08% |
| 2015-03-31 | -31.83% |
| 2014-12-31 | -36.46% |
| 2014-09-30 | -27.11% |
| 2014-06-30 | -39.10% |
| 2014-03-31 | -29.15% |
| 2013-12-31 | -21.91% |
| 2013-09-30 | -50.17% |
| 2013-06-30 | -33.96% |
